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A great majority of epidemiological studies still relies on the use of single reference intervals regardless of age and sex differences in platelet count (9) . Similarly, most laboratories in Western Countries still adopt standard ranges for classification of thrombocytopenia or thrombocytosis (generally 150 to 400 or 450x10 9 platelets/L for all people).
A recent paper (9) has provided new data to overcome the use of single reference interval by identifying age-sex specific cut-offs derived from a large epidemiological setting including three population-based studies on 40,987 inhabitants of seven Italian areas.
We aimed to assess the predictive values of these newly defined ranges of platelet count (Table 1) for all-cause mortality.
According to Biino et al (9) , low platelet count was defined as platelet number <156 ×10 9 /L or <140×10 9 /L for women aged <64 years and for those aged >64 years respectively; for men, low platelet count was defined as platelet number<141×10 9 /L or <122×10 9 /L for men aged <64 years or >64 years, respectively. Cut-offs for high platelet count were set when platelet count > 405×10 During a median follow-up of 7.6 years (interquartile range: 6.7 to 8.6 years; 163,659 person/years), 1,001 deaths were recorded. The incidence rates and the risk of all-cause mortality among the participants in the different platelet count groups are shown in Table 1 .
As compared to the normal range, lower platelet number was significantly related to increased risk of mortality in the multivariable model (HR=2.17; 95%CI 1.55-3.05). Conversely higher platelet count was not associated with higher risk of death (Table 1) . Comparison with usual ranges used for classifying thrombocytopenia and thrombocytosis (platelet count <150x10 9 /L or >400x10 9 /L, respectively, 5) is also reported in Table 1 . According to the standard classification, which does not account for age and sex differences in platelet count, about 2.9% of the study population would be classified as having thrombocytopenia. At variance, the newly defined ranges in platelet count only identified 1.8% of the population as being at higher risk of death because of low platelet count.
We also found that subjects classified as thrombocytopenic by traditional range intervals (150-400x10 9 /L) had a significantly higher risk of all-cause mortality than subjects with normal platelet count or thrombocytosis (HR 1.62; 95%CI 1.28-2.05). As compared to subjects included in the normal platelet count category for both criteria, those who shifted from thrombocytopenia -as defined by usual ranges (<150 x10 
85). For comparison, subjects who were
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From considered as having thrombocytopenia according to both classifications,(n=358, n of deaths=36) had a relative risk of death of 2.22 (95%CI 1.57-3.13). The number of individuals who shifted from normal values (by traditional ranges) to thrombocytopenia (according to new ranges) was too small (n=36, n of deaths=1; HR=4.01; 95%CI 0.56-28.8) to allow any meaningful risk interpretation.
A cubic spline was also generated and showed a U-shaped relationship between platelet number and overall mortality. Findings revealed a non-linear relationship (p value =0.0015) with lower platelet count at higher risk for total mortality, in comparison with normal or higher values (Figure 1 ).
To the best of our knowledge, this is the first study to test the association of age and sex specific ranges of platelet count with risk of all-cause mortality in a large population-based epidemiological cohort.
Using personalized (sex and age specific) rather than traditional reference intervals of platelet count reduces the number /proportion of subjects with thrombocytopenia, as lately observed in a sample of Italian adult patients to whom the newly identified cut-offs were applied (11).
The group of possibly true thrombocytopenic subjects (identified by personalized range intervals) had a higher risk of total mortality as compared to subjects classified as thrombocytopenic by traditional range intervals.
Strengths of the present study are represented by the large number of subjects and its prospective design. In addition, a large number of possible confounding factors have been considered, including C-reactive protein, mean platelet volume and use of antiplatelet drugs. A major limitation is the unavailability of cause-specific deaths.
In conclusion, it is suggested that introducing the new platelet count ranges into clinical practice would reduce the number/proportion of normal individuals unduly considered at high risk of allcause mortality and would be useful to better identify those subjects at higher mortality risk, possibly related to a low platelet count. Contribution: LI, GdG, MB, CC, MBD, ADiC contributed to the conception and design of the work, and interpretation of data; SC, ADC managed data collection; MB, ADiC analysed the data; MB wrote the paper; MBD, GdG, CC and LI originally inspired the research and critically reviewed the manuscript.
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